June 23, 2003
Forbes Medi-Tech Sells Andro Business
VANCOUVER, British Columbia
Forbes Medi-Tech Inc. (NASDAQ:FMTI)sold its pharmaceutical fine chemicals business, which focused on processtechnologies for androstenedione and androstadienedione, to an unnamedmulti-national pharmaceutical company. The sale gave the company $1.9 million ingross proceeds. This initiative is in line with Forbes streamlined focus ongenerating revenue for its nutraceutical business.
For more information, visit www.forbesmedi.comor Booth #4807 at the IFT Food Expo.
You May Also Like
Advancing gender equity in the nutraceutical industrySep 25, 2023
CRN petition to FTC: RCTs aren’t required to substantiate ‘health-benefit’ claimsSep 22, 2023
Collagen peptide ingredient solutions for seniors’ changing needs – infographicSep 19, 2023
Radicle Insights—Covid Eris and dietary supplements: separating fact from fictionSep 21, 2023